AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Description: Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine Placebo
Description: Eflornithine placebo \[three tablets orally once a day\]
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac 150 MG
Description: Sulindac \[one tablet orally once a day\]
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac 150 MG
Description: Sulindac \[one tablet orally once a day\]
Study NCT01483144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac placebo
Description: Sulindac placebo \[one tablet orally once a day\]
Study NCT00295815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
Study NCT00295815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Description: 100-130 mg/m2, oral once, every 6 weeks until PD
Study NCT03997487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOFTEE
Description: Smartphone app for taking quality images of conjunctivae
Study NCT01901822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutured together
Description: The soft tissue and the allograft will be sutured together using a continuous sling suture.
Study NCT01901822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutured separately
Description: The soft tissue and the allograft will be sutured separately using a continuous sling suture.
Study NCT04027413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortisip compact protein
Description: (24% protein; 41% carbohydrate; 35% fat)
Study NCT04027413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: preOp
Description: (100% carbohydrate).
Study NCT00770471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00770471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Study NCT00770471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Study NCT00770471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00770471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Study NCT00770471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study NCT00770471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00770471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00770471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01563913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
Study NCT01563913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill, taken for 1.5 years
Study NCT02328937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: spherical hydrophilic soft contact lens worn in a daily wear modality
Study NCT02765789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (Immunosorba)
Description: Immunoadsorption as an alternative to plasma exchange
Study NCT04232904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominous plane block (TAP Block)
Description: TAP block which is a peripheral nerve block preferred to postoperative pain management.
Study NCT00636415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
Study NCT00960362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-009
Description: Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
Study NCT00960362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
Study NCT02328937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Study NCT03181347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RYGB
Description: Roux-en-Y Gastric Bypass
Study NCT03181347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SG
Description: Sleeve Gastrectomy
Study NCT03181347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and behavioral
Description: Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
Study NCT00919204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
Study NCT00398281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: Given orally
Study NCT00398281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03670251 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5747
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00979953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03681743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study NCT03755011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: white noise
Description: Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
Study NCT03755011 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: normal ICU activity noise
Study NCT04283708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submental liposuction
Description: Advancement Genioplasty With Submental Liposuction
Study NCT02409095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-HB-Hib vaccine
Description: Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
Study NCT02409095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP-HB-Hib vaccine
Description: Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
Study NCT02409095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Syringe Jet Injector (DSJI)
Description: Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
Study NCT02409095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Needle & Syringe
Description: The conventional needle syringe that is routinely used for vaccination.
Study NCT00981539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enema
Description: pre operative rectal enema~one adult bottle to be used rectally the night before surgery
Study NCT01234883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple electrolyte solution
Description: IV multiple electrolyte solution dosed as clinically indicated for rehydration
Study NCT01234883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: IV solutions dosed as clinically indicated for rehydration
Study NCT02342990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit
Description: CogMed: an home-based and computer-based solution to improve working memory deficit
Study NCT02342990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit
Description: CogMed: an home-based and computer-based solution to improve working memory deficit
Study NCT02342990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cluster A No training. Delay start of CogMed
Description: No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
Study NCT01481688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
Study NCT01481688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra time
Description: An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
Study NCT03193463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (<=8cc)
Description: In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Study NCT03193463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (>8cc)
Description: In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Study NCT03193463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: an investigational device, will be used to deliver the topotecan
Study NCT03193463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: to monitor the infusion of topotecan into the tumor
Study NCT03193463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Does Topotecan
Description: Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Study NCT04339660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 1\*10E6 UC-MSCs /kg body weight suspended in 100mL saline
Study NCT04339660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL saline intravenously
Study NCT02328937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Study NCT02429479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known
Description: Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
Study NCT02429479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard advance care planning
Description: This is a online simple living will form.
Study NCT04412083 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PPA Tele-Savvy Pilot Intervention
Description: We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
Study NCT01543022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony
Description: The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
Study NCT01543022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker
Description: The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
Study NCT00787306 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active risk factor surveillance
Description: Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
Study NCT00787306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active risk factor surveillance
Description: Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
Study NCT03405077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT Online Training
Description: First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training.
Study NCT03486483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
Study NCT02615509 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Imaging on experimental tomo device
Description: The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
Study NCT01526837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
Study NCT02738645 — intervention group
Intervention type: OTHER
Intervention: pneumonia
Study NCT03002142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Phonak Audéo B-R (Target V 5.0)
Study NCT03002142 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phonak Audéo B-R (Target V 5.0) without amplification
Study NCT01717079 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: 120 pulses 0.2Hz
Study NCT01717079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 120 pulses 0.2Hz
Study NCT04118413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
Study NCT00193479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT00193479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone
Study NCT00193479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine
Study NCT00193479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone
Study NCT00193479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab
Study NCT01416857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RDDT
Study NCT04575181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
Study NCT04575181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: For s.c. injection once daily for 26 weeks
Study NCT04575181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (NNC0268-0965)
Description: For s.c. injection once daily for 26 weeks
Study NCT04575181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (insulin glargine)
Description: For s.c. injection once daily for 26 weeks
Study NCT03321110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dextrin)
Study NCT03321110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 150 mg or 300 mg
Study NCT02021110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
Study NCT01727362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + acupuncture
Description: Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
Study NCT01727362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients of this group receive usual care only
Study NCT03983434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study NCT03267446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Doppler Ultrasound
Description: 3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
Study NCT04329572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
Study NCT01476800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 OCAS
Description: oral
Study NCT01476800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: oral
Study NCT03256357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
Study NCT03256357 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
Study NCT03256357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation training
Description: Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.